Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AVITA MedicalASX:AVH -0.33%58 Days Sales Outstanding is 41.55 as of Jun. 2026, which is 21% below its 10-year median of 52.92. GuruFocus rates ASX:AVH with a GF Score™ of 58/100 and a GF Value™ of A$2.93 (Fairly Valued). The stock has 8 warning signs investors should review. Among 809 Medical Devices & Instruments companies, AVITA Medical ranks better than 73.3% on this metric.
AVITA Medical's average Accounts Receivable for the
three
months ended in Jun. 2026 was A$14.1 Mil. AVITA Medical's Revenue for the
three
months ended in Jun. 2026 was A$30.9 Mil.
Hence, AVITA Medical's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 41.55.
The historical rank and industry rank for AVITA Medical's Days Sales Outstanding or its related term are showing as below:
ASX:AVH'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.61 Med: 52.92 Max: 490.16
Current: 47.48
During the past 13 years, AVITA Medical's highest Days Sales Outstanding was 490.16. The lowest was 34.61. And the median was 52.92.
ASX:AVH's Days Sales Outstanding is ranked better than 73.3% of 809
companies
in the Medical Devices & Instruments industry
Industry Median: 64.94
vs ASX:AVH: 47.48
AVITA Medical's Days Sales Outstanding
declined
from Jun. 2025 (58.93) to Jun. 2026 (41.55).
AVITA Medical (ASX:AVH) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
AVITA Medical Days Sales Outstanding Related Terms
AVITA Medical Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for AVITA Medical's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVH vs TMCI, VMD, TLSI: Days Sales Outstanding Comparison
For the Medical Devices subindustry, AVITA Medical's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where AVITA Medical's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (ASX:AVH) has a Days Sales Outstanding of 41.55 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on AVITA Medical and its competitors. This is 21% below median its historical median of 52.92. Over the past decade, AVITA Medical's Days Sales Outstanding has ranged from 34.61 to 490.16. According to the industry distribution chart, AVITA Medical ranks #216 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 26.7%.
Is AVITA Medical's Days Sales Outstanding too high?
AVITA Medical's current Days Sales Outstanding of 41.55 is 21% below median its 10-year median of 52.92. Over the past 10 years, this metric has ranged from a low of 34.61 to a high of 490.16. The Medical Devices & Instruments industry median Days Sales Outstanding is 64.94. AVITA Medical's value of 41.55 is 36% below this industry median. Based on the distribution chart, AVITA Medical ranks #216 out of 809 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, AVITA Medical has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's Days Sales Outstanding compare to TMCI and VMD?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #216 out of 809 companies for Days Sales Outstanding. This puts AVITA Medical in the upper half of its industry. The industry median Days Sales Outstanding is 64.94. AVITA Medical's value of 41.55 is 36% below this benchmark. Historically, AVITA Medical's own Days Sales Outstanding has ranged from 34.61 to 490.16 over the past decade. While the company's 10-year median is 52.92 vs. the industry median of 64.94, AVITA Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 64.94, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AVITA Medical's current Days Sales Outstanding of 41.55 is 36% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on AVITA Medical and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 64.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current Days Sales Outstanding is 41.55, which is 21% below median its own 10-year median of 52.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (ASX:AVH) is currently considered Fairly Valued. The stock's GF Value™ is A$2.93, compared to a current price of A$3.01 — trading 2.7% above its estimated fair value. The current Days Sales Outstanding is 41.55, which is 21% below median its 10-year median of 52.92 and 36% below the Medical Devices & Instruments industry median of 64.94. AVITA Medical's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For AVITA Medical (ASX:AVH), the current Days Sales Outstanding is 41.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AVITA Medical (ASX:AVH) Overvalued in 2026?
Based on GuruFocus' analysis, AVITA Medical stock appears to be overvalued.
The current stock price of A$3.01 is trading 2.7% above its estimated GF Value™ of A$2.93.
GuruFocus considers AVITA Medical to be Fairly Valued.
Key valuation signals for ASX:AVH:
Days Sales Outstanding: 41.55 (21% below median its 10-year median of 52.92)
GF Value™: A$2.93 vs. price of A$3.01 (2.7% above fair value)
Industry Position: 36% below the Medical Devices & Instruments median (#216 of 809)
No single metric tells the full story. See the ASX:AVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
58GF Score
Get the complete analysis for ASX:AVH
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVH has been successfully added to your 
